2021 PRESENTING COMPANIES
January 28th, 2021 at the following time:
1:00PM - 4:30PM Eastern Time
Allotex Inc. is an ophthalmic biologics and device company developing new therapeutic solutions for improving the vision of millions of patient’s using allogeneic therapies. Allotex delivers scalable, quality-controlled vision correction and eye care products based on ethically sourced allogeneic material. Allotex is a start-up company led by Drs. David Muller and Michael Mrochen.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. Eyenovia recently submitted a US FDA NDA for MydCombi™, its product candidate for mydriasis.”
Kedalion Therapeutics is focused on revolutionizing the delivery of topical ocular medicine to significantly increase patient comfort and ease of use. Kedalion’s AcuStreamTM technology is being developed for delivery of topical drugs to the eye in a precise and accurate manner that will enable comparable therapy with an 80% reduction in dose relative to standard drops. The potential for reduced side effects and increased patient comfort is intended to transform the concept of simplicity, convenience and adherence in self-administered care for leading ocular diseases.
LensGen® is an ophthalmic medical device company that has developed a biomimetic, Curvature Changing Fluid-Optic Intraocular Lens designed for the treatment of cataracts and presbyopia.
Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 2 and Phase 3 trials. For more information, please visit www.ocuphire.com.
Omega Ophthalmics, LLC is a startup co-founded by serial entrepreneur, Rick Ifland, and ophthalmologist, Gary Wortz, MD, to develop an entirely new class of intraocular lenses with the goals of improving refractive outcomes and future-proofing the eye for the advancements in the future.
Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical company focused on developing an innovative eye drop for the treatment of presbyopia symptoms. Promising results from a well powered Phase 2b study have paved an informed path for Orasis to advance their product candidate through successful initiation of Phase 3 studies, NEAR-1 and NEAR-2. Orasis’ differentiated formulation with an optimal balance between efficacy, safety and comfort, along with a proven commercialization strategy in place, positions the company as an emerging leader in the presbyopia space. Follow us on LinkedIn to learn more.
Visus Therapeutics is a clinical-stage company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates. For more information, visit: www.visustx.com and follow us on Twitter (@VisusTx) and on LinkedIn.
Yolia Health has developed a contact lens and eye drop solution platform of treatments that correct vision problems like presbyopia, hyperopia, myopia/myopia progression, and post-refractive errors. How does it work? Our specially designed GP contact lenses and eye drops reshape the cornea. Patients use our TVT treatment (contact lenses + eye drops) for only 7 days to enjoy 12 months lens free. Our treatment is binocular, safe, repeatable, and reversible.